"As the CEO of Pfizer, a company he first joined in 1993, Bourla-a veterinarian by training-led the company through the pandemic. His team worked around the clock to deliver products to combat the crisis-Pfizer collaborated with startup BioNTech to bring the first FDA-approved COVID-19 vaccine to market; it also introduced Paxlovid, the first antiviral medicine customized to fight COVID. Business soared to record revenue."
""At the top of the hill, you are the best company," Bourla told me during a recent episode of my vodcast, Fortune 500: Titans and Disruptors. "You are named the best CEO. The people at Pfizer are the most proud employees in the world. Suddenly, to have a financial drop, it hurts a lot, and that creates emotional reactions for everyone in the company, including me.""
Albert Bourla led Pfizer through the COVID-19 pandemic, collaborating with BioNTech to deliver the first FDA-approved COVID-19 vaccine and introducing Paxlovid, the first antiviral customized to fight COVID. Pandemic success drove record revenue, with COVID-related sales exceeding $56 billion in 2022 and falling to around $5 billion today. The company now confronts patent cliffs and a sharp revenue decline that has created emotional reactions across the organization. Bourla is positioning Pfizer for new moonshots, targeting GLP-1 drugs and cancer treatments, and emphasizes resilience and determination rooted in his personal background and leadership approach.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]